BIM
LAB icon

BlackRock Investment Management’s Standard BioTools LAB Stock Holding History

BlackRock Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$850K Sell
116,811
-746
-0.6% -$4.68K ﹤0.01% 2788
2016
Q3 		$942K Buy
117,557
+7,689
+7% +$70.6K ﹤0.01% 2718
2016
Q2 		$992K Buy
109,868
+6,429
+6% +$60.4K ﹤0.01% 2644
2016
Q1 		$835K Buy
103,439
+1,670
+2% +$12K ﹤0.01% 2605
2015
Q4 		$1.1M Buy
101,769
+923
+0.9% +$9.06K ﹤0.01% 2537
2015
Q3 		$818K Sell
100,846
-2,081
-2% -$32.8K ﹤0.01% 2744
2015
Q2 		$2.49M Buy
102,927
+20,648
+25% +$652K ﹤0.01% 2049
2015
Q1 		$3.46M Buy
82,279
+1,242
+2% +$49.1K ﹤0.01% 1651
2014
Q4 		$2.73M Sell
81,037
-749
-0.9% -$21.2K ﹤0.01% 1799
2014
Q3 		$2M Buy
81,786
+793
+1% +$22.3K ﹤0.01% 2003
2014
Q2 		$2.38M Buy
80,993
+10,951
+16% +$351K ﹤0.01% 1948
2014
Q1 		$3.09M Buy
70,042
+163
+0.2% +$7.17K ﹤0.01% 1743
2013
Q4 		$2.67M Sell
69,879
-2,162
-3% -$63.7K ﹤0.01% 1808
2013
Q3 		$1.58M Buy
72,041
+5,362
+8% +$105K ﹤0.01% 2123
2013
Q2 		$1.16M Buy
+66,679
New +$1.17M ﹤0.01% 2250

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's LAB Position: Q4 2016 in Review

BlackRock Investment Management reduced its Standard BioTools (LAB) stake by 0.63% in Q4 2016, selling an estimated $4.68K and leaving 116,811 shares worth $850K. The position accounts for ﹤0.01% of the portfolio, ranked #2788.

BlackRock Investment Management first reported a position in LAB in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.46M in Q1 2015. 83 funds tracked by Wall St. Rank hold LAB as of Q4 2016.

  • BlackRock Investment Management held 116,811 shares of Standard BioTools worth $850K as of Q4 2016.
  • BlackRock Investment Management sold 746 Standard BioTools shares in Q4 2016, an estimated $4.68K.
  • Standard BioTools made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2788 holding.
  • BlackRock Investment Management first reported a position in Standard BioTools in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Standard BioTools position peaked at $3.46M in Q1 2015.
  • 83 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.